Diet-induced insulin resistance elevates hippocampal glutamate as well as VGLUT1 and GFAP expression in AβPP/PS1 mice. by Hascup, Erin R et al.
Southern Illinois University Carbondale
OpenSIUC
Articles Neurology
11-25-2018
Diet-induced insulin resistance elevates
hippocampal glutamate as well as VGLUT1 and
GFAP expression in AβPP/PS1 mice.
Erin R Hascup
Sarah O Broderick
Mary K Russell
Yimin Fang
Andrzej Bartke
See next page for additional authors
Follow this and additional works at: https://opensiuc.lib.siu.edu/neurology_articles
This Article is brought to you for free and open access by the Neurology at OpenSIUC. It has been accepted for inclusion in Articles by an authorized
administrator of OpenSIUC. For more information, please contact opensiuc@lib.siu.edu.
Recommended Citation
Hascup, Erin R, Broderick, Sarah O, Russell, Mary K, Fang, Yimin, Bartke, Andrzej, Boger, Heather A and Hascup, Kevin N. "Diet-
induced insulin resistance elevates hippocampal glutamate as well as VGLUT1 and GFAP expression in AβPP/PS1 mice.." Journal of
Neurochemistry (Nov 2018). doi:10.1111/jnc.14634.
Authors
Erin R Hascup, Sarah O Broderick, Mary K Russell, Yimin Fang, Andrzej Bartke, Heather A Boger, and Kevin
N Hascup
This article is available at OpenSIUC: https://opensiuc.lib.siu.edu/neurology_articles/5
*Department of Neurology, Center for Alzheimer’s Disease and Related Disorders, Neurosciences
Institute, Springﬁeld, Illinois, USA
†Department of Pharmacology, Southern Illinois University School of Medicine, Springﬁeld, Illinois,
USA
‡Department of Neuroscience, Center on Aging, Medical University of South Carolina, Charleston,
South Carolina, USA
§Division of Geriatric Research, Department of Internal Medicine, Southern Illinois University School
of Medicine, Springﬁeld, Illinois, USA
Abstract
The symptomologies of Alzheimer’s disease (AD) develop over
decades suggesting modiﬁable lifestyle factors may contribute
to disease pathogenesis. In humans, hyperinsulinemia associ-
ated with type 2 diabetes mellitus increases the risk for
developing AD and both diseases share similar age-related
etiologies including amyloidogenesis. Since we have demon-
strated that soluble Ab42 elicits glutamate release, wewanted to
understand how diet-induced insulin resistance alters hip-
pocampal glutamate dynamics, which are important for memory
formation and consolidation. Eight to twelve-week-old C57BL/
6J and AbPP/PS1 mice were placed on either a low-fat diet or
high-fat diet (HFD) for 8 months. A HFD led to signiﬁcant weight
increases as well as impaired insulin sensitivity, glucose
tolerance, and learning in both C57BL/6J and AbPP/PS1 mice.
AbPP/PS1 low-fat diet mice had elevated hippocampal basal as
well as stimulus-evoked glutamate release that was further
increased with consumption of a HFD. Immunohistochemistry
indicated an increase in vesicular glutamate transporter 1 and
glial ﬁbrillary acidic protein density in hippocampal subregions
corresponding with this elevated extracellular glutamate. While
no differences in hippocampal plaque load were observed, the
elevated astrogliotic response surrounding the plaques in
AbPP/PS1 HFD mice may have been a compensatory mech-
anism to control plaque accumulation. These data support that
AbPP/PS1 mice have chronically elevated extracellular gluta-
mate that is exacerbated by a HFD and that modiﬁable lifestyle
factors such as obesity-induced insulin resistance can con-
tribute to AD pathogenesis.
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Alzheimer’s disease (AD) is an age-related neurodegenera-
tive disorder characterized by a slow, but progressive,
accumulation of extracellular aggregated beta-amyloid (Ab)
and intracellular hyperphosphorylated tau tangles (Jack et al.
2013). This accumulation leads to alterations in neurotrans-
mitter dynamics, synapse loss, and cerebral atrophy that
culminate in the eventual cognitive and functional decline
associated with the disorder (Mota et al. 2014). To date,
current therapeutics target cholinesterase inhibitors, to
increase acetylcholine levels, or antagonism of the
N-methyl-D-aspartate (NMDA) receptor, to prevent gluta-
mate-mediated excitotoxicity (Cummings et al. 2014; Godyn
et al. 2016). However, these therapies have limited efﬁcacy,
only treat symptoms, and do not decelerate disease progres-
sion, possibly because they are administered at advanced AD
stages. Without a well-established biomarker for AD, early
diagnosis is difﬁcult and underscores the lack of disease-
modifying pharmacotherapy options. To further complicate
diagnosis, evidence supports that AD symptomology devel-
ops over decades and modiﬁable lifestyle factors, such as
obesity-induced type 2 diabetes mellitus (T2DM), may
contribute to AD progression (Barnes and Yaffe 2011).
The peptide hormone, insulin, regulates glucose uptake
and storage in the periphery and brain for use in energy
production (Felice 2013). However, excessive caloric con-
sumption, particularly of hydrogenated or saturated fats,
promotes a cascade of metabolic events starting with elevated
circulating insulin concentrations that leads to insulin
resistance and increases the risk factor for developing
T2DM (Holland et al. 2007). In fact, T2DM and AD share
several age-related etiologies including hyperinsulinemia,
insulin resistance, hyperglycemia, amyloidogenesis, and
memory impairment (Zhao and Townsend 2009; Talbot
et al. 2012; Moloney et al. 2010). These similar sympto-
mologies suggest insulin resistance and the subsequent onset
of T2DM is a risk for developing AD (Vandal et al. 2014).
In support of this, the Mayo Clinic Alzheimer Disease Patient
Registry has reported that 80% of their AD patients had
either T2DM or impaired glucose tolerance (Janson et al.
2004) and T2DM in midlife increases the odds for develop-
ing mild cognitive impairment or AD later in life by 1.5- to
2-fold (Allen et al. 2004; Ott et al. 1999; Arvanitakis et al.
2004). While the mechanistic link between T2DM and AD is
not fully elucidated, the metabolic hypothesis of AD which
supports altered insulin signaling promotes a cascade of
neurological events that initiate the pathogenesis of AD
(Hoyer 2002). For example, brain insulin-degrading enzyme
(IDE) regulates the metabolism of both insulin and Ab, but at
a lower afﬁnity for the latter. As such, hyperinsulinemia
prevents IDE from degradation of monomeric Ab leading to
its accumulation and aggregation (Farris et al. 2003). These
small molecular weight isoforms of Ab (monomers, dimers,
and trimers) are hypothesized to be the bioactive component
that causes synaptic dysfunction, neurotoxicity, and the
eventual neurodegeneration associated with AD (Jin and
Selkoe 2015; Yang et al. 2017).
Prior studies have demonstrated that soluble Ab42 elicits
glutamate release through the a7 nicotinic acetylcholine
receptor (a7nAChR; Talantova et al. 2013; Hascup and
Hascup 2016). Because of glutamate’s role in learning and
memory, it is hypothesized that persistent, excessive synaptic
glutamate overstimulates the NMDA receptor thereby pre-
venting the detection of physiological signals leading to
cognitive impairment (Parsons et al. 2007). In fact, our
laboratory has demonstrated that double transgenic mice
expressing a mutant amyloid precursor protein (Mo/
HuAPP695swe) and Presenilin 1 (PS1-dE9) genes (AbPP/
PS1) have elevated hippocampal glutamate as early as 2–
4 months of age, prior to the onset of cognitive decline
(Hascup and Hascup 2015). While previous studies have
demonstrated that HFD exacerbates cognitive decline and
disease neuropathology in animal models of AD (Vandal
et al. 2014; Knight et al. 2014; Theriault et al. 2016; Julien
et al. 2010), alterations to memory-associated neurotrans-
mitters have not been elucidated. The aim of the present
study was to address how obesity-induced insulin resistance
alters glutamate dynamics in both cognitively normal and
AbPP/PS1 mice predisposed to AD pathology. Since previ-
ous studies have shown that HFD affects memory in
cognitively normal rodents (Kanoski and Davidson 2011;
Cordner and Tamashiro 2015), non-AD control mice help to
understand changes associated with, or independent from, the
metabolic hypothesis of AD pathogenesis.
Materials and methods
Animals
Protocols for animal use were approved by the Laboratory Animal
Care and Use Committee at Southern Illinois University School of
Medicine (Protocol #219-14-003) and the study was not preregis-
tered. Eight- to twelve-week-old male, C57BL/6J (RRID:
IMSR_JAX:000664) and AbPP/PS1 (RRID:MMRRC_034832-
JAX; Mo/HuAPP695swe/PS1-dE9), mice were obtained from
Jackson Laboratory (Bar Harbor, ME, USA), and group housed on
a 12:12-h light: dark cycle with food and water available ad libitum.
All experiments were conducted during the light phase. Genotype
was conﬁrmed by TransnetYX, Inc (Cordova, TN, USA). All mice
were ear tagged with unique numerical identiﬁers so as to blind
researchers throughout the experimental paradigms. Pseudorandom-
ization using the Microsoft Excel 2013 randomization function to
generate random decimal numbers between 0 and 1 for each mouse
and dietary treatment. These random numbers were then sorted into
ascending order generating a list that categorized mice into the
following groups: C57BL/6J low-fat diet (LFD), C57BL/6J HFD,
AbPP/PS1 LFD, and AbPP/PS1 HFD. Similar methodology was
used to determine the order of which animals were assessed. A
n = 15 for all treatment groups was allocated at study initiation;
however, due to animal loss from normal aging and disease
progression, the following indicates the remaining number of
animals available at the end of the 8-month dietary treatment:
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C57BL/6J LFD (n = 14), C57BL/6J HFD (n = 11), AbPP/PS1 LFD
(n = 11), and AbPP/PS1 HFD (n = 12). All of these remaining mice
underwent blood glucose monitoring, cognitive assessment, in vivo
glutamate recordings, and immunohistochemical (IHC) analysis
except for one AbPP/PS1 HFD mouse that died during in vivo
glutamate recordings as outlined in Fig. 1a. Following in vivo
electrochemistry, all mice were killed by an overdose of isoﬂurane
followed by rapid decapitation with sharp scissors.
Chemicals
All chemicals were prepared and stored according to manufacturer
recommendations unless otherwise noted. L-glutamate oxidase (EC
1.4.3.11) was obtained from Cosmo Bio USA Co. (Carlsbad, CA,
USA; Cat: YMS-80049) and reconstituted in distilled, deionized
water to make a 1 U/lL stock solution and stored at 4°C. Sodium
phosphate monobasic monohydrate (Cat: BP330-500), sodium
phosphate dibasic anhydrous (Cat: S375-500), 1,3-phenylenediamine
Fig. 1 Experimental design, mouse weight, and blood glucose mea-
surements. (a) An outline of the experimental design. Abbreviations:
intraperitoneal insulin tolerance test (ipITT), intraperitoneal glucose
tolerance test (ipGTT), Morris water maze (MWM). (b) Analysis of
mouse weight gain through 28 weeks on either LFD or high-fat diet
(HFD). Results from the 4-h fasting ipITT and 15-h fasting ipGTT.
Mouse genotypes and diet group are indicated on each graph. (c)
Four-hour fasting blood glucose prior to ip injection of 1 IU/kg b.w. of
insulin, (d) blood glucose during the 120-min ipITT, (e) area under the
curve of the 120-min ipITT, (f14-h fasting blood glucose prior to ip
injection of 2 g/kg b.w. of glucose, (g) blood glucose during the 120-
min ipGTT, (h) area under the curve of the 120-min ipGTT. *p < 0.05,
**p < 0.01, ****p < 0.0001 C57BL/6J LFD (n = 14) versus C57BL/6J
HFD (n = 11); #p < 0.05, ##p < 0.01, ####p < 0.0001 AbPP/PS1 LFD
(n = 11) versus AbPP/PS1 HFD (n = 12); §p < 0.05, §§p < 0.01,
§§§p < 0.001 C57BL/6J LFD versus AbPP/PS1 LFD; where n refers
to the number of animals.
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dihydrochloride (mPD; Cat: P017225G), sodium chloride (Cat: S271-
3), calcium chloride dehydrate (Cat: BP510-100), dextrose monohy-
drate (Cat: D15-500), and hydrogen peroxide (H2O2; Cat: H325-100)
were obtained from Thermo Fisher Scientiﬁc (Waltham, MA, USA).
L-glutamic acid sodium salt (Cat: G1626), potassium chloride (Cat:
P9333), bovine serum albumin (BSA; Cat: A3059), glutaraldehyde
(Cat: G5882), dopamine hydrochloride (DA; Cat: H8502), L-ascorbic
acid (AA; Cat: A7056), and dibutyl phthalate and xylene (Cat: 06522)
were obtained from Sigma-Aldrich Co. (St. Louis, MO, USA). Rabbit
polyclonal glial ﬁbrillary acidic protein (GFAP) antibody was
obtained from Dako (Carpinteria, CA, USA; RRID:AB_10013382).
Guinea pig polyclonal vesicular glutamate transporter 1 (VGLUT1)
antibody was obtained fromMillipore (Burlington, MA, USA; RRID:
AB_2301751). Biotinylated goat anti-rabbit serum (RRID:
AB_2313606), biotinylated goat anti-guinea pig serum (RRID:
AB_2336132), avidin–biotin complex kit (RRID:AB_236818), and
VIP peroxidase substrate kit (RRID:AB_2336819) were obtained
from Vector Laboratories (Burlingame, CA, USA). Amylo-Glo
RTDTM with ethidium bromide (EtBr) was obtained from Biosensis
(Temecula, CA, USA; Cat: TR-400-AG).
Low-fat and high-fat diet
Allmicewere switched from standard rodent chow (13%kcal fat, 57%
kcal carbohydrate, 30% kcal protein, 4% sucrose, 4.09 kcal/gm;
LabDiet; Cat: 5001) to either a LFD (10% kcal fat, 70% kcal
carbohydrate, 20% kcal protein, 7% sucrose, 3.85 kcal/gm; Cat:
D12450J) or a HFD (60% kcal fat, 20% kcal carbohydrate, 20% kcal
protein, 7% sucrose, 5.24 kcal/gm; Cat: D12492) obtained from
ResearchDiets Inc. (NewBrunswick, NJ, USA). A LFDdiet was used
as the control diet so as to match protein and sucrose content with the
HFD. Mouse weight was monitored throughout the study (Fig. 1b).
Intraperitoneal insulin tolerance test (ITT) and glucose tolerance
test (GTT)
To determine insulin sensitivity, an initial blood glucose measure-
ment (time = 0) was taken from the tail vein of 4-h fasted mice and
measured using a Presto glucometer (AgaMatrix, Salem, NH,
USA) followed by intraperitoneal (ip) injection of 1 IU/kg body
weight (b.w.) Humulin R (Henry Schein, Melville, NY, USA: Cat:
1238578). To determine glucose tolerance, an initial blood glucose
measurement was taken (time = 0) from 15-h fasted mice followed
by an ip injection of 2 g of glucose/kg b.w. Following either
injection, blood glucose levels were measured sequentially at 15, 30,
45, 60, and 120 min (Fang et al. 2017).
Morris water maze
The morris water maze (MWM) paradigm consisted of two
consecutive training days where the mouse learned to remain on
the platform for 60 s before rescue. For the ﬁrst training day, a
visible platform protruded 1 cm out of the opaque pool of water to
aid in platform location. Mice underwent three consecutive 60-s
maximum trials with a 15-min intertrial interval. On the second
training day, the visible platform was removed and mice underwent
three training blocks (30-min interblock interval) of 3, 60-s
maximum trials (15-min intertrial interval) to learn the location of
the submerged platform (1 cm below the surface). Starting quadrant
was varied for each trial. The probe challenge consisted of a single
60-s trial. The ANY-maze video tracking system (Stoelting Co.,
Wood Dale, IL, USA; RRID:SCR_014289) records and analyzes
maze navigation. The three training sessions for Day 1 and for each
training block in Day 2 were averaged.
Enzyme-based microelectrode arrays
Enzyme-based MEAs with platinum (Pt) recording surfaces were
fabricated, assembled, coated, and calibrated for in vivo mouse
glutamate measurements as previously described (Burmeister
et al. 2000; Hascup et al. 2006, 2013). One of the MEA
(Quanteon LLC; Cat: R2) Pt sites was coated with an L-
glutamate oxidase, BSA, glutaraldehyde solution. BSA and
glutaraldehyde increase the adhesion and crosslink L-glutamate
oxidase to the MEA surface, while L-glutamate oxidase enzy-
matically degrades glutamate to a-ketoglutarate and H2O2, the
electroactive reporter molecule. The second Pt recording site (self-
referencing or sentinel site) was coated with a BSA and
glutaraldehyde solution that is unable to enzymatically generate
H2O2 from L-glutamate. A potential of +0.7V versus a Ag/AgCl
reference electrode was applied to the Pt recording surfaces,
resulting in a two electron oxidation of H2O2, and the subsequent
current was ampliﬁed and digitized by the fast analytical sensing
technology 16mkIII (Quanteon, LLC; Nicholasville, KY) electro-
chemistry instrument.
mPD Electropolymerization
Pt recording surfaces were electroplated with 5 mM mPD in 0.05 M
phosphate-buffered saline for 20 min to restrict the passage of AA,
DA, uric acid, and 3,4-dihydroxyphenylacetic acid (Hascup et al.
2016).
Calibration
MEAs were calibrated in 0.05 M phosphate-buffered saline
(37°C) to create a standard curve for the conversion of current
to glutamate concentration. Final beaker concentrations of
250 lM AA, 20, 40, and 60 lM L-glutamate, 2 lM DA, and
8.8 lM H2O2 were used to assess MEA performance. A total of
49 MEAs were used in the present study. The average 
standard error of the mean (SEM) for glutamate sensitivity was
5.7  0.3 pA/lM (R2 = 0.998  0.001), selectivity ratio of
367  48 to 1, and limit of detection of 0.20  0.03 lM based
on a signal-to-noise ratio of 3.
In Vivo anesthetized recordings
A glass micropipette (World Precision Instruments, Inc.; Cat:
1B100-6) was used for local application studies. The tip of the
micropipette (12–15 lm internal diameter) was positioned between
the pair of recording sites and mounted ~100 lm above the MEA
surface. Mice were anesthetized using 1.5% isoﬂurane (Henry
Schein; Cat: 029405) in a calibrated vaporizer (Parkland Scientiﬁc;
V3000) and placed in a stereotaxic frame with a mouse anesthesia
mask (David Kopf Instruments; Cat: 900/907). Body temperature
was maintained at 37°C. The MEA/micropipette assembly was
lowered into the dentate gyrus (DG; AP: 2.0, ML:  1.0, DV:
2.2 mm), CA3 (AP: 2.0, ML:  2.0, DV: 2.2 mm), and
CA1 (AP: 2.0, ML:  1.0, DV: 1.7 mm) from Bregma
(Paxinos and Franklin 2004). A Ag/AgCl reference wire was
positioned beneath the skull and rostral to the right hemisphere
craniotomy. Constant voltage amperometry (4 Hz) was performed
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using the fast analytical sensing technology 16mkIII. Calibration
data in conjunction with a MATLAB (MathWorks, Natick, MA,
USA; RRID:SCR_014289) graphic user interface program (Ver-
sion 6.1) was used to calculate extracellular glutamate. The
sentinel site current (pA) was subtracted from the glutamate
recording site current (pA) and divided by the slope (pA/lM)
obtained during the calibration (Burmeister and Gerhardt 2001;
Burmeister et al. 2002; Hascup et al. 2010, 2011).
Immunohistochemistry and semi-quantification
Following in vivo electrochemistry, the brains were removed and
post-ﬁxed in 4% paraformaldehyde for 48 h and then transferred
into 30% sucrose in 0.1 M PB for 24 h prior to sectioning. Forty-
ﬁve micron sections of the hippocampus were obtained using a
Microm cryostat (Zeiss; Cat: HM 500). Serial sections (every
sixth) of the hippocampus were processed for free-ﬂoating
immunohistochemistry (IHC) using rabbit polyclonal GFAP
(1 : 2000) or guinea pig polyclonal VGLUT1 antibody
(1 : 1000) (Farrand et al. 2017; Hascup et al. 2016). Endogenous
peroxidase activity was quenched by treating sections with 10%
H2O2 in 20% methanol for 10 min. Sections for primary antibodies
were permeabilized in Tris-buffered saline with 0.25% TritonX-
100 following treatment for 20 min with sodium metaperiodate.
Nonspeciﬁc binding was controlled by 1-h incubation in 10%
normal goat serum. Sections were incubated overnight in the
primary antibody at 23C. The next day, sections were incubated
for 1 h with the secondary antibody (1 : 200; biotinylated goat
anti-rabbit serum or biotinylated goat anti-guinea pig serum) and
1 h with the Vectastain avidin–biotin complex kit (Vector). The
reaction was developed using the VIP peroxidase substrate kit
(Vector) to enhance the reaction and produce a color stain. This
reaction was stopped using 0.1 M PB, and the sections were
mounted on glass slides, dehydrated, and coverslipped with dibutyl
phthalate and xylene. To control for staining intensity, staining of
all sections for each antibody was conducted on the same day and
developed with VIP for the same amount of time (GFAP: 3 min,
VGLUT1: 2 min). For plaque staining, slides containing serial
sections (every sixth) of the hippocampus were incubated for
10 min in freshly prepared Amylo-Glo RTDTM solution followed
by a 5-min rinse in 0.9% saline without shaking, then 1-min
incubation with EtBr based on product protocol (1 : 100). Staining
intensities of GFAP, VGLUT1, and plaque formation in the
hippocampus were determined using National Institutes of Health
Image J Software 1.48 (RRID:SCR_003070) to measure a gray
scale value within the range of 0–256, where 0 represents white
and 256 represents black (Farrand et al. 2017). A template for the
DG, CA3, and CA1 hippocampal subregions was created for
VGLUT1 and GFAP while a template for the whole hippocampus
was created for plaque formation. Templates were used on all
brains similarly, and images were captured with a Nikon Eclipse
E-600 microscope equipped with an Olympus-750 video camera
system and a Dell Pentium III computer. Measurements were
performed blinded, and approximately six sections were averaged
to obtain one value per subject. If six sections per stain were not
obtained, the subject was excluded from data analysis. Staining
density was obtained when background staining was subtracted
from mean staining intensities on every sixth section through the
hippocampus.
Ab42 ELISA
A separate cohort of mice was used for insoluble Ab42 determina-
tion. Mice were killed as described above and the hippocampus was
dissected and stored at 80°C until tissue processing. Protein
concentrations were determined using the bicinchoninic acid
method, and the assessment of the insoluble fractions of Ab42 was
performed using the Human/Rat b amyloid (42) ELISA kit (WAKO
Chemicals; Cat: 292-64501).
Data analysis
Sample size was determined based on previous MWM, electro-
chemical, and IHC data using C57BL/6J and AbPP/PS1 mice. A
power calculation indicated a minimum of 10 mice per group for
MWM and electrochemical recordings and ﬁve mice per group for
IHC analysis (Boger et al. 2007; Hascup and Hascup 2015) to
detect differences with 95% conﬁdence (a = 0.05) and 0.8 power.
Prism (GraphPad Software, Inc., La Jolla, CA, USA; RRID:
SCR_002798) software was used for all statistical analyses includ-
ing D’Agostino-Pearson omnibus normality tests. A one-way
analysis of variance (ANOVA) was used for MWM and for
electrochemical stimulus volume comparisons, while a two-way
ANOVA (diet vs genotype) was used for all other analyses. When the
ANOVA indicated a statistically signiﬁcant main effect, a Holm-
Sidak’s multiple comparisons post hoc test was used. Outliers were
determined with a single Grubb’s test (a = 0.05). Data are
represented as mean  SEM and signiﬁcance was deﬁned as
p < 0.05. The unit of analysis ‘n’ for each dataset refers to the
number of mice and data are available upon request.
Results
Changes in weight gain induced by a HFD
An outline of the experimental design is presented in Fig. 1a.
All mice were given a 2-week acclimation period when they
arrived at our animal facility, placed on standard chow for
2 weeks, and weighed weekly until study completion
(Fig. 1b). Following the 2-week acclimation period, pseu-
dorandomization was used to assign mice to either the
C57BL/6J LFD (n = 14), C57BL/6J HFD (n = 11), AbPP/
PS1 LFD (n = 11), or AbPP/PS1 HFD (n = 12) groups. All
mice remained on their respective diets until study comple-
tion. A diet effect was observed at 4 weeks (F[3,
44] = 81.29; p < 0.0001). As expected, both C57BL/6J
and AbPP/PS1 mice on HFD gained more weight compared
to genotype-matched LFD groups No differences in weight
gain were observed between genotypes within each diet
group.
HFD impairs peripheral insulin sensitivity
After 24 weeks on their respective diets, the effects of a HFD
on the sensitivity of blood glucose levels to the action of
insulin were tested with an ipITT. No difference in blood
glucose levels was observed during a 4-h fast (Fig. 1c). A
HFD signiﬁcantly impaired peripheral insulin sensitivity
compared to genotype-matched LFD mice when examining
the 120-min blood glucose response to the insulin challenge
© 2018 International Society for Neurochemistry, J. Neurochem. (2018) 10.1111/jnc.14634
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(F[3, 44] = 23.58; p < 0.0001; Fig. 1d) as well as the
subsequent area under the curve analysis (F[1, 44] = 45.41;
p < 0.0001; Fig. 1e) indicating an obesity-induced T2DM
phenotype. Additionally, an effect of genotype (F[1,
44] = 15.61; p = 0.0003) was observed supporting that
AbPP/PS1 mice have impaired insulin sensitivity that is
independent of diet (Fig. 1d and e).
Glucose metabolism is impaired in mice fed a HFD
The effects of a HFD on glucose metabolism were tested
using the ipGTT. Mice fed a HFD had signiﬁcantly (F[1,
44] = 42.28; p < 0.0001; Fig. 1f) elevated 15 h fasting
blood glucose compared to genotype-matched LFD mice as
a result of the obesity-induced insulin resistance. Mice fed a
HFD-metabolized glucose slower during the 120-min glu-
cose challenge (F[3, 44] = 8.019; p = 0.0002) and subse-
quent area under the curve analysis (F[1, 44] = 18.32;
p < 0.0001) compared to genotype-matched LFD mice
(Fig. 1g and h).
Mice on a HFD have impaired spatial learning and memory
One week following ipGTT and 27 weeks into dietary
feeding, mice underwent a 3-day MWM. The MWM tests
spatial learning and memory recall by requiring the mouse to
utilize visual cues to repeatedly swim to a static, submerged
platform, regardless of the starting quadrant. During the
MWM, mice were trained to locate a visible escape platform
on Day 1 and a hidden platform on Day 2. The visible
platform veriﬁes visual acuity while simultaneously habitu-
ating the mice to the novel environment thereby reducing
stress while encouraging a motivation to escape the pool
(Gulinello et al. 2009). The three training sessions for Day 1
and for each training block in Day 2 were averaged for
individual mice for analysis. Latency to reach to the platform
as well as cumulative distance from the platform was
assessed. Cumulative distance is a proximity measure
designed to reﬂect search error through summation of the
distance from the platform calculated at 1-s intervals while
accounting for trial variations in starting quadrant and
swimming speed (Gallagher et al. 2015). As shown in
Fig. 2a, AbPP/PS1 HFD took longer to locate the hidden
escape platform during the ﬁrst training block of Day 2
compared to their Day 1 performance (F[3, 44) = 4.118;
p = 0.0117). In Fig. 2b, C57BL/6J LFD mice were the only
group that did not travel further from the hidden escape
platform on the ﬁrst training block of Day 2 and continued to
signiﬁcantly decrease over successive training blocks (F[3,
52] = 3.449; p = 0.0231) compared to their Day 1 perfor-
mance. On the contrary, the other three groups of mice
traveled further from the hidden escape platform on the ﬁrst
training block of Day 2, which was signiﬁcant in AbPP/PS1
HFD mice (F[3, 44] = 5.178; p = 0.0038) compared to their
Day 1 performance. While C57BL/6J HFD and both AbPP/
PS1 diet groups decreased the cumulative distance from the
hidden escape platform over successive training blocks, a
signiﬁcant improvement over Day 1 performance was not
observed supporting decreased learning in these three groups
of mice. During the MWM probe challenge for memory
recall, no differences were observed in the number of annulus
40 crossings (Fig. 2c).
Fig. 2 MWM Training and Probe Challenge. The 2-day MWM training
session consisted of a visible platform on Day 1 that was changed to a
hidden platform on Day 2 and the probe challenge. (a) Latency to
reach the escape platform for each training session. (b) The cumulative
distance each mouse spent away from the platform for the training
sessions. A & B) *p < 0.05, **p < 0.01, hidden platform versus Day 1
visible platform. (c) The number of annulus 40 crossings. C57BL/6J
LFD, n = 14; C57BL/6J high-fat diet (HFD), n = 11; AbPP/PS1 LFD,
n = 11; AbPP/PS1 HFD, n = 12; where n refers to the number of
animals.
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HFD elevates hippocampal basal glutamate
A minimum of 2-week post-MWM (29 weeks into dietary
feeding) an enzyme-based MEA was used to measure
glutamate dynamics in the DG, CA3, and CA1. Represen-
tative glutamate traces showing basal and stimulus-evoked
glutamate release are presented in Fig. 3. Basal glutamate
was calculated by taking a 10-s baseline average prior to the
start of pressure ejection in the DG, CA3, and CA1. When
examining basal glutamate (Fig. 4a–c), a genotype effect was
only observed in the CA1 (F[1, 43] = 12.23; p = 0.0011),
indicating increased tonic glutamate in AbPP/PS1 mice. A
diet effect was observed in the DG (F[1, 43] = 6.232;
p = 0.0165), CA3 (F[1, 43] = 12.90; p = 0.0008), and CA1
(F[1, 43] = 12.78; p = 0.0009), supporting that a HFD
elevates basal glutamate with synergistic effects observed in
AbPP/PS1 mice.
HFD alters hippocampal glutamate dynamics
A glass micropipette attached to the enzyme-based MEA was
used to locally apply sterile ﬁltered (0.20 lm) 70 mM KCl
(70 mM KCl, 79 mM NaCl and 2.5 mM CaCl2, pH 7.4) by
pressure ejection (5–15 psi, 1–2 s pulses) using a Picosprit-
zer III (Parker-Hannaﬁn Corp.). Ejection volumes were
maintained between 100 and 200 nl in each hippocampal
subﬁeld and monitored using a stereomicroscope (Luxo
Corp. Cat:, Elmsford, NY, USA) ﬁtted with a calibrated
reticule (Hascup and Hascup 2016). Similar volumes of
stimulus were locally applied in the DG (F[3, 40] = 0.7720;
p = 0.5165), CA3 (F[3, 40] = 0.3397; p = 0.7967), and CA1
(F[3, 41] = 1.655; p = 0.1915) of all mouse groups to elicit
glutamate release (Fig. 4d–f). A genotype effect was
observed in the DG (F[1,40] = 8.429; p = 0.0060), CA3
(F[1, 40] = 4.720; p = 0.0358), and CA1 (F[1, 41] = 7.559;
Fig. 3 Stimulus-evoked glutamate release traces. Representative
traces of glutamate release from 70 mM KCl stimulation. Columns
indicate genotype and diet while rows indicate hippocampal subﬁeld.
Within each panel, the inset trace depicts the reproducibility of the
glutamate signals with the dashed box indicating a single response
magniﬁed beneath for a clearer presentation of glutamate dynamics.
Concentration and time axes are consistent in all panels for compar-
ative interpretation.
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p = 0.0088), whereby AbPP/PS1 mice release more gluta-
mate upon depolarization. A diet effect was observed in the
DG (F[1, 40] = 12.57, p = 0.0010) and CA1 (F[1,
41] = 5.772; p = 0.0209), but not the CA3 (F[1,
40] = 0.0870; p = 0.7695), indicating a HFD increased
stimulus-evoked glutamate release. The clearance of gluta-
mate is predominantly mediated by uptake in high-efﬁciency
excitatory amino acid transporters (EAAT) located on glia
Fig. 4 Hippocampal Glutamate Measures. Basal glutamate, stimulus-
evoked glutamate release, and evoked glutamate uptake rate in the
DG (a, d, g), CA3 (b, e, h), and CA1 (c, f, i). Basal glutamate was
measured prior to local application of stimulus. Stimulus volumes
(mean  SEM) are shown beneath the bar graphs in (d–f). *p < 0.05,
**p < 0.01 C57BL/6J LFD (n = 13–14; one subject excluded) versus
C57BL/6J high-fat diet (HFD) (n = 10–11; one subject excluded);
#p < 0.05 AbPP/PS1 LFD (n = 10–11; one subject excluded) versus
AbPP/PS1 HFD (n = 11; one subject died); §p < 0.05 C57BL/6J LFD
(n = 13–14) versus AbPP/PS1 LFD (n = 10–11); ‡p < 0.05 C57BL/6J
HFD (n = 10) versus AbPP/PS1 HFD (n = 11); where n refers to the
number of animals and at most a single subject per group was
excluded by Grubb’s test.
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(Zhou and Danbolt 2013). A signiﬁcant effect of genotype
was observed for glutamate uptake rate in the DG (F[1,
42] = 6.050; p = 0.0181) and CA3 (F[1, 42] = 5.793;
p = 0.0206), but not the CA1 (Fig. 4g–i). A signiﬁcant
effect from diet led to increased glutamate uptake rate only in
the CA1 (F[1, 40] = 5.721; p = 0.0216).
Increased expression of VGLUT1 in HFD mice
IHC was used to determine changes in VGLUT1 expression
in the DG, CA3, and CA1. Representative images of
VGLUT1 from the DG are shown in Fig. 5a–d (409
magniﬁcation) and average mean density for each hippocam-
pal subﬁeld is presented in Fig. 5e–g. A signiﬁcant effect of
genotype on VGLUT1 expression was observed in the DG (F
[1, 34] = 12.40; p = 0.0012), CA3 (F[1, 33] = 12.59;
p = 0.0012), and CA1 (F[1, 36] = 32.74; p < 0.0001),
supporting that the elevated hippocampal basal and stimu-
lus-evoked glutamate release in APP/PS1 mice is a result of
increased glutamatergic vesicles. Likewise, a signiﬁcant
effect of diet existed on VGLUT1 expression in the DG (F
[1, 34] = 17.67; p = 0.0002), CA3 (F[1, 33] = 27.63;
p < 0.0001), and CA1 (F[1, 36] = 17.54; p = 0.0002),
indicating that a HFD increased glutamatergic vesicles
corresponding with the elevated hippocampal glutamate.
GFAP expression is increased by HFD
IHC was used to determine changes in GFAP expression in
the DG, CA3, and CA1. Whole hippocampal representative
images (109 magniﬁcation) of GFAP expression are shown
in Fig. 6a–d and average mean density for each hippocampal
subﬁeld is presented in Fig. 6e–g. A signiﬁcant effect of
genotype on GFAP expression was observed in the DG (F[1,
36] = 14.83; p = 0.0005), CA3 (F[1, 37] = 23.07;
p < 0.0001), and CA1 (F[1, 39] = 100.60; p < 0.0001), as
indicated by greater hippocampal GFAP expression in APP/
PS1 mice. In addition, a signiﬁcant effect of diet exists on
GFAP expression in the C57BL/6J DG (F[1, 36] = 9.006;
p = 0.0049) and AbPP/PS1 CA3 (F[1, 37] = 20.13;
p < 0.0001) and CA1 (F[1, 39] = 15.98; p = 0.0003),
indicating that a HFD results in greater astrogliosis.
A HFD does not alter plaque formation
Hippocampal plaque formation was determined by staining
with Amylo-Glo RTDTM. Whole hippocampal representa-
tive images (109 magniﬁcation) of plaque accumulation
(blue) and EtBr counter-stain (red) are shown in Fig. 7a–d
and average mean density of whole hippocampal plaque
accumulation is presented in Fig. 7e. As indicated by the
arrows in Fig. 7c and d, a genotype effect caused increased
Fig. 5 VGLUT1 Immunohistochemistry. Representative images of
VGLUT1 staining in the DG at 409 magniﬁcation from C57BL/6J
LFD (a), C57BL/6J high-fat diet (HFD) (b), AbPP/PS1 LFD (c), and
AbPP/PS1 HFD (d) mice. Scale bar = 50 lm. Average mean density
of VGLUT1 staining in the DG (e), CA3 (f), and CA1 (g). *p < 0.05,
***p < 0.001 C57BL/6J LFD (n = 11–13; 1–3 subjects excluded)
versus C57BL/6J HFD (n = 7–8; 3–4 subjects excluded); ##p < 0.01,
###p < 0.001 AbPP/PS1 LFD (n = 6–7; 4–5 subjects excluded) versus
AbPP/PS1 HFD (n = 11–12; one subject excluded); §p < 0.05,
§§p < 0.01 AbPP/PS1 LFD (n = 6–7) versus C57BL/6J LFD (n = 11–
13); ‡p < 0.05, ‡‡p < 0.01, ‡‡‡‡p < 0.0001 AbPP/PS1 HFD (n = 11–12)
versus C57BL/6J HFD (n = 7–8); where n refers to the number of
animals.
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plaque accumulation (F[1, 16] = 1410.0; p < 0.0001). How-
ever, a diet effect was not observed (F[1, 16] = 0.1096;
p = 0.7449), indicating that a HFD does not increase plaque
deposition in AbPP/PS1 mice. This was further supported by
ELISA determination in a separate cohort of mice showing a
genotype effect (F[1, 24] = 49.95; p < 0.0001), but not a
diet effect (F[1, 24] = 0.79; p = 0.3828).
Discussion
Half of AD cases are attributable to modiﬁable lifestyle
factors (Barnes and Yaffe 2011) including obesity-induced
T2DM that has been suggested to increase the risk for
developing AD 1.5- to 2-fold (Allen et al. 2004; Ott et al.
1999; Arvanitakis et al. 2004). While the exact molecular
events linking T2DM to AD have not been fully elucidated,
the metabolic hypothesis of AD (Hoyer 2002) which
supports impaired insulin signaling initiates a series of
events including Ab accumulation (Farris et al. 2003),
neuroinﬂammation (Granic et al. 2009), oxidative stress
(De Felice and Ferreira 2014), and calcium dyshomeostasis
(Zhang et al. 2017) leading to AD pathogenesis. The results
of the present study support addition of elevated hippocam-
pal glutamatergic signaling to this growing body of molec-
ular parallels.
In the present study, starting at 3 months of age, C57BL/6J
and AbPP/PS1 mice were placed on either LFD (10% kcal
from fat) or HFD (60% kcal from fat) with matching protein
and sucrose content. Mice fed a HFD developed an obese
phenotype starting 1 month after diet initiation and contin-
ued until study completion. Since insulin sensitivity is
positively correlated with increased longevity and health
span in vertebrates (Arum et al. 2014), we choose to
examine peripheral blood glucose clearance in these mice.
The obese phenotype resulted in impaired peripheral insulin
signaling and glucose tolerance as observed in the ipITT and
ipGTT. The insulin resistance observed in the HFD mouse
groups explains the elevated 15 h fasting blood glucose
Fig. 6 Glial ﬁbrillary acidic protein (GFAP) immunohistochemistry.
Whole hippocampal representative images of GFAP staining in
C57BL/6J LFD (a), C57BL/6J high-fat diet (HFD) (b), AbPP/PS1 LFD
(c), and AbPP/PS1 HFD (d) mice at 109 magniﬁcation. Average mean
density of GFAP staining in the DG (e), CA3 (f), and CA1 (g). *p < 0.05
C57BL/6J LFD (n = 13–14; one subject excluded) versus C57BL/6J
HFD (n = 7–8; 3–4 subjects excluded); ###p < 0.001, ###p < 0.0001
AbPP/PS1 LFD (n = 7–10, 1–4 subjects excluded) versus AbPP/PS1
HFD (n = 11–12; 1 subject excluded); §p < 0.05, §§§§p < 0.0001 AbPP/
PS1 LFD (n = 7–10) versus C57BL/6J LFD (n = 13–14); ‡p < 0.05,
‡‡‡‡p < 0.0001 AbPP/PS1 HFD (n = 11–12) versus C57BL/6J HFD
(n = 7–8); where n refers to the number of animals.
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levels compared to genotype-matched LFD groups. Interest-
ingly, AbPP/PS1 mice fed a LFD had a similar metabolic
proﬁle to HFD mice supporting a naturally occurring insulin
resistance in these mice, which has been reported elsewhere
(Pedros et al. 2014; Macklin et al. 2017). Despite the innate
insulin resistance observed in AbPP/PS1 mice, HFD led to a
further disruption of their metabolic proﬁle.
A HFD has been shown to negatively affect learning and
memory in cognitively normal rodents (Kanoski and David-
son 2011; Cordner and Tamashiro 2015) as well as
exacerbate cognitive decline and AD-related neuropathology
in animal models (Vandal et al. 2014; Knight et al. 2014;
Theriault et al. 2016; Julien et al. 2010). For this study, diet
treatments began prior to the onset of typically reported AD-
related pathology and continued through an age when
pathology and plaque burden are well developed in the
AbPP/PS1 mouse model. During the visible portion (Day 1)
of the MWM behavioral task, similar performances in the
latency to the platform and cumulative distance traveled from
the platform were observed in all groups of mice, indicating
comparable visual acuity and physical activity despite weight
differences. Learning impairments in AbPP/PS1 mice were
discerned during the second training day with the hidden
escape platform. Throughout the training blocks, we
observed that a higher percentage of C57BL/6J LFD and
HFD mice successfully navigate the MWM while traveling
less distance from the platform. To the contrary, AbPP/PS1
mice presented with learning impairments that were worsened
when fed aHFD as supported by 1) a slower escape latency and
2) the cumulative distance from the submerged escape
platform during the ﬁrst two training blocks. By the third
training block, AbPP/PS1 performance was similar to that
observed during the Day 1 visible platform, but no signiﬁcant
improvements were observed. However, during the MWM
probe challenge on the third day, no differences in the number
of annulus 40 crossing was observed. The MWM paradigm
employed in this study, while atypical from previously
published reports from our laboratory (Hascup and Hascup
2015), was designed to reduce stress and anxiety in the mouse.
The visible platform on Day 1 helped to habituate mice to the
novel pool environment while testing for visual acuity since
some inbred mouse strains develop retinal degeneration
Fig. 7 Amyloid Plaque Formation. Whole hippocampal representative
images of amyloid plaque formation (blue) and nuclei staining (red) by
EtBr in C57BL/6J LFD (a), C57BL/6J high-fat diet (HFD) (b), AbPP/
PS1 LFD (c), and AbPP/PS1 HFD (d) mice at 109 magniﬁcation.
Arrows indicate plaque formations in (c) and (d). Average mean density
of plaque formation in the hippocampus (e) and insoluble Ab42 ELISA
determination (f). §§§§p < 0.0001 AbPP/PS1 LFD (n = 5,9) versus
C57BL/6J LFD (n = 5,8); ‡‡‡‡p < 0.0001 AbPP/PS1 HFD (n = 5,7)
versus C57BL/6J HFD (n = 5,4), where n refers to the number of
animals and seven subjects per group were excluded from IHC plaque
analysis.
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(Chang et al. 2002). Furthermore, the shorter training duration
avoided learning limitations from multiple practice sessions,
prevented fatigue, and increased throughput (Alamed et al.
2006). These data support that a HFD can negatively affect
learning in both C57BL/6J and AbPP/PS1 mice.
Glutamate, the predominant excitatory neurotransmitter in
the mammalian CNS, plays an essential role in learning and
memory (Riedel et al. 2003) and has been implicated in
several neurodegenerative disorders including Huntington’s,
Parkinson’s, and Alzheimer’s diseases. To measure gluta-
mate, we used an enzyme-based MEA with high spatial
resolution (50 9 100 lm recording sites) that allowed for
independent measures from the DG, CA3, and CA1 dorsal
hippocampus, a region that is important for consolidation and
retrieval of spatial memory during the MWM task (Cimadev-
illa et al. 2005). In the present study, AbPP/PS1 LFD mice
exhibited elevated basal glutamate (CA1) and stimulus-
evoked glutamate release (DG, CA3, and CA1) compared to
C57BL/6J LFD mice. The elevated basal glutamate may
result from a combination of mechanisms affecting soluble
Ab42 levels that are known to elicit glutamate release
(Hascup and Hascup 2016; Talantova et al. 2013). First, the
transgene expressions in AbPP/PS1 result in progressive
Ab42 accumulation (Alley et al. 2010), and second, the
insulin resistance observed in these mice may prevent IDE
from degrading monomeric Ab42 leading to further accumu-
lation and overactivation of a7nAChR on presynaptic
glutamatergic terminals. Since hippocampal tissue was used
for IHC, none was available for biochemical analysis.
Further studies examining soluble Ab42 are needed in order
to validate this hypothesis.
VGLUT1, the predominant subtype of vesicles that store
hippocampal glutamate (Liguz-lecznar and Skangiel-
kramska 2007), was increased in the CA3 and CA1 of
AbPP/PS1 LFD compared to C57BL/6J LFD mice.
Increased expression of VGLUT1 has been demonstrated
to cause excess glutamate release (Daniels et al. 2011);
however, homeostatic mechanisms exist to limit aberrant
synaptic ﬁring that may arise from environmental or genetic
variations. But, during the early stages of AD, it is
hypothesized that these negative feedback mechanisms begin
to destabilize in cortical and hippocampal regions (Frere and
Slutsky 2018). For example, epileptiform spikes have been
observed in both AbPP/PS1 mice (Minkeviciene et al. 2009)
and amnestic mild cognitively impaired patients (Vossel
et al. 2013) as well as hyperexcitability of CA1 pyramidal
neurons in AbPP/PS1 mice (Siskova et al. 2014). This
hyperexcitability coupled with the increased VGLUT1
expression may explain the increased stimulus-evoked
glutamate release observed throughout the hippocampus of
the present study.
Both C57BL/6J and AbPP/PS1 mice fed a HFD presented
with elevated basal (CA3 and CA1) and stimulus-evoked
glutamate release (DG and CA1) compared to
genotype-matched LFD mice. As described above, the
increased extracellular glutamate observed in AbPP/PS1
HFD mice may be explained by the accumulation of Ab42
stimulating glutamate release, but this would not be the case
in C57BL/6J HFD mice. However, a HFD would initiate a
cascade of separate events in both genotypes leading to the
increased basal and stimulus-evoked glutamate release. The
insulin resistance and subsequent increase in circulating
blood glucose levels observed in both HFD mice would lead
to an increase in neuronal glucose accumulation. Since
neuronal glutamate synthesis can be derived from glucose
(Sonnewald 2014), the higher blood glucose levels would
increase the neurotransmitter pool of glutamate, which is
supported by the elevated VGLUT1 density observed in the
DG, CA3, and CA1 of HFD mice.
A HFD can up-regulate glial glutamate transporter
expression while increasing the maximal velocity of clear-
ance (Valladolid-Acebes et al. 2012). While the present
study did not examine EAAT density, increased expression
of GFAP is indicative of astrogliosis (Brahmachari et al.
2006) that is associated with an increase in glial glutamate
transporters in response to chronic cerebral injuries and
neurodegenerative disorders (Haroon et al. 2017). At ﬁrst,
this appears counterintuitive. More transporters support faster
glutamate clearance that would decrease basal and evoked
glutamate concentrations. But, elevated glutamate release
causes increased EAAT density as a mechanism to prevent
chronic accumulation of extracellular glutamate and potential
excitotoxicity (Munir et al. 2000). Although not signiﬁcant
in all hippocampal subregions, stimulus-evoked glutamate
uptake was increased in AbPP/PS1 LFD versus diet-matched
C57BL/6J mice and a HFD further increased these rates in
the DG and CA3. In other words, glutamate uptake rate
generally increased in response to increases in basal and
stimulus-evoked glutamate release.
As expected, hippocampal plaque pathology was only
observed in AbPP/PS1 mice; however, a HFD did not
increase plaque density which is similar to previous reports
in these mice (Theriault et al. 2016). This may be due to the
astrogliotic response to control plaque deposition in the
pathogenesis of AD (Kraft et al. 2013). As such, we
observed increased hippocampal GFAP density in AbPP/
PS1 LFD and HFD compared to diet-matched C57BL/6J
control mice that did not present with plaque pathology.
GFAP density throughout the hippocampus was further
elevated in AbPP/PS1 HFD compared to LFD mice, but this
was only mildly observed in the DG of C57BL/6J HFD mice.
Since astroglia play a role in Ab clearance (Ries and Sastre
2016), the elevated astrogliotic inﬂammatory response,
particularly in AbPP/PS1 HFD mice, may have prevented
additional plaque accumulation.
The elevated extracellular hippocampal glutamate levels
observed in C57BL/6J HFD as well as AbPP/PS1 LFD and
HFD mice would contribute to their decreased performance
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on the MWM task reported here and elsewhere (Theriault
et al. 2016). The NMDA receptor is important for spatial
learning and memory tasks (Morris et al. 1986), but mild,
chronic overactivation would be detrimental to synaptic
plasticity. This argument is based on the signal-to-noise
hypothesis of NMDA receptor activation. Elevated tonic
glutamate levels (as observed in this study) prevent the
detection of phasic signals thereby blocking formation of
new learning (Parsons et al. 2007). This process could occur
over an extended period of time before calcium overload,
excitotoxicity, and eventual neurodegeneration as observed
in AD. As such, this mechanism helps to explain the
cognitive-improving effects of memantine, an NMDA
receptor antagonist, in some AD patients (Parsons et al.
2007). In support of this, AbPP/PS1 mice fed a HFD
followed by treatment with memantine saw signiﬁcant
reductions in insulin resistance, neuroinﬂammation, and
cognitive deﬁcits (Ettcheto et al. 2018). Alternatively, a
HFD has been shown to decrease NMDA receptor subunit
GluN2B leading to desensitization that may account for
cognitive deﬁcits (Valladolid-Acebes et al. 2012).
The concentration of extracellular basal glutamate is
debated throughout the scientiﬁc literature with reports
ranging from nanomolar to micromolar concentrations (Her-
man and Jahr 2007; Burmeister et al. 2013; Messam et al.
1995). These discrepancies are frequently attributed to
methodological considerations that often times yield similar
results when additional factors are taken into consideration.
The size of our MEA recording sites limits our recording
capabilities to the extracellular matrix (ECM) where we are
measuring glutamate release and clearance from multiple
synapses. As such, a summation of multiple extrasynaptic
spillover events may cause elevated levels compared to those
reported using patch clamp techniques in slice preparations.
Additionally, the diffusion capabilities of neurotransmitters
and other membrane impermeable molecules in the ECM are
subject to both volume fraction (a = 0.2) and tortuosity (k =
1.6) (Sykova andNicholson 2008). The a effectively ampliﬁes
the concentration of extrasynaptic spillover of glutamate in the
ECMwhile the k simultaneously slows down its diffusion and
uptake into high-afﬁnity transporters. Furthermore, the depo-
larizing stimulus used in the present study creates a positive net
charge on the ECM resulting in a drag effect on the negatively
charged glutamate molecules (Gundelﬁnger et al. 2010) and
changes the membrane potential which EAATs rely upon for
efﬁcient uptake of glutamate (Takahashi et al. 1997). The net
effect is a slower clearance of stimulus-evoked glutamate
release when compared to other methods. Of course, tissue
damage is always a concern with any invasive technique
including, but not limited to, slice preparations, microdialysis,
and MEA recordings. However, the ceramic substrate (Al2O3)
on the MEAs used in this study have good biocompatibility
helping to limit CNS damage allowing for single-unit neuronal
activity measurements for at least 6 months post-implantation
(Hascup et al. 2009). The MEAs employed in this study have
routinely demonstrated that basal extracellular glutamate are
sensitive to Na+-channel (tetrodotoxin), Ca2+-channel (x-
conotoxin), and EAAT (DL-threo-b-Benzyloxyaspartic acid)
blockade lending credence to a healthy parenchyma surround-
ing the implanted MEA (Hascup et al. 2010; Hascup and
Hascup 2016; Hascup et al. 2007). Furthermore, the extra-
cellular glutamate concentrations reported in this manuscript
fall below the Km (~20 lM) for EAATs (Zhou and Danbolt
2013). Moreover, basal hippocampal glutamate concentra-
tions for C57BL/6J LFDmice (~1 lM) are below the reported
EC50 (3.7 lM) for the NR1/NR2B NMDA receptor (Banke
and Traynelis 2003), further strengthening our premise that
chronic overactivation of NMDA receptors, as observed in the
HFD and AbPP/PS1 groups would be detrimental to synaptic
plasticity, cognition, and may lead to eventual neurodegener-
ation. Regardless, the current study was not designed to be a
deﬁnitive assessment of basal glutamate concentrations. In
fact, the level of basal glutamate is dependent on a number of
criteria including transporter density (Herman and Jahr 2007),
ECM developmental stage (Gundelﬁnger et al. 2010), and the
glia–neuron ratio (Azevedo et al. 2009) resulting in marked
variation between brain regions, maturation, and species
(Burmeister et al. 2013).
Conclusion
Excitotoxicity is a proposed mechanism underlying the
neurodegeneration associated with AD. However, the basal
and stimulus-evoked glutamate release values reported here
are not considered neurotoxic for an intact nervous system.
Rather, the current study (when combined with previous
research from our laboratory) highlights a consistent theme
of elevated hippocampal glutamate starting as early as 2–
4 months in AbPP/PS1 mice (Hascup and Hascup 2015) that
is potentially mediated by soluble Ab42 (Hascup and Hascup
2016). Furthermore, obesity-induced insulin resistance
caused cognitive impairments and increased extracellular
glutamate in AbPP/PS1 mice. The progressive deposition of
Ab42 with AD progression may chronically elevate glutamate
leading to the cognitive and function decline observed in AD,
which can be exacerbated by modiﬁable lifestyle factors such
as obesity-induced insulin resistance. While additional
studies are ongoing to elucidate mechanisms associated with
dietary inﬂuences on glutamate dynamics in AbPP/PS1 mice,
hippocampal glutamate levels may serve as a viable early
therapeutic biomarker for AD pathogenesis.
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